BIOACTIVATION AND BIOINACTIVATION OF DRUGS AND DRUG METABOLITES - RELEVANCE TO ADVERSE DRUG-REACTIONS

被引:20
作者
PARK, BK
PIRMOHAMED, M
TINGLE, MD
MADDEN, S
KITTERINGHAM, NR
机构
[1] Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, Merseyside L69 3BX
关键词
D O I
10.1016/0887-2333(94)90029-9
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Adverse drug reactions that cannot be predicted from the pharmacological properties of the drug and which are not easily reproduced in laboratory animals are a major complication of drug therapy. It is necessary to investigate the mechanisms of such reactions in order to (1) define structural features within a given drug molecule which are responsible for causing toxicity and (2) to identify those individuals who are particularly sensitive to a given drug reaction. In theory, drug toxicity may arise by direct toxicity, genotoxicity or immune-mediated toxicity caused by either parent drug or chemical. In this respect chemically reactive metabolites are of particular importance and the balance between bioactivation and bioinactivation pathways of drug metabolism will be a critical factor in both the type and extent of toxicity. We have therefore developed in vitro techniques that incorporate human cells for the detection and characterization of stable, chemically reactive and cytotoxic metabolites. In such experiments bioactivation (by CYP1A, CYP2D6, CYP3A, etc.) can be investigated by use of a liver bank, while lymphocytes provide accessible human cells, which can be obtained from both patients and volunteers, genotyped and/or phenotyped for particular drug-metabolizing enzymes (eg. glutathione transferase mu). The relevance of in vitro experiments to drug toxicity observed in humans will be illustrated by reference to studies with anticonvulsants and antimalarials.
引用
收藏
页码:613 / 621
页数:9
相关论文
共 43 条
[1]   MONITORING EXPOSURE TO 4,4'-METHYLENEDIANILINE BY THE GAS-CHROMATOGRAPHY MASS-SPECTROMETRY DETERMINATION OF ADDUCTS TO HEMOGLOBIN [J].
BAILEY, E ;
BROOKS, AG ;
BIRD, I ;
FARMER, PB ;
STREET, B .
ANALYTICAL BIOCHEMISTRY, 1990, 190 (02) :175-181
[2]   DRUG PROTEIN CONJUGATES .18. DETECTION OF ANTIBODIES TOWARDS THE ANTIMALARIAL AMODIAQUINE AND ITS QUINONE IMINE METABOLITE IN MAN AND THE RAT [J].
CHRISTIE, G ;
BRECKENRIDGE, AM ;
PARK, BK .
BIOCHEMICAL PHARMACOLOGY, 1989, 38 (09) :1451-1458
[3]   DETECTION OF ANTIDRUG IGG ANTIBODIES IN PATIENTS WITH ADVERSE DRUG-REACTIONS TO AMODIAQUINE [J].
CLARKE, JB ;
NEFTEL, K ;
KITTERINGHAM, NR ;
PARK, BK .
INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY, 1991, 95 (04) :369-375
[4]   IMMUNOGENICITY OF AMODIAQUINE IN THE RAT [J].
CLARKE, JB ;
MAGGS, JL ;
KITTERINGHAM, NR ;
PARK, BK .
INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY, 1990, 91 (04) :335-342
[5]   THE USE OF CIMETIDINE AS A SELECTIVE INHIBITOR OF DAPSONE N-HYDROXYLATION IN MAN [J].
COLEMAN, MD ;
SCOTT, AK ;
BRECKENRIDGE, AM ;
PARK, BK .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (05) :761-767
[6]   THE USE OF CIMETIDINE TO REDUCE DAPSONE-DEPENDENT METHEMOGLOBINEMIA IN DERMATITIS-HERPETIFORMIS PATIENTS [J].
COLEMAN, MD ;
RHODES, LE ;
SCOTT, AK ;
VERBOV, JL ;
FRIEDMANN, PS ;
BRECKENRIDGE, AM ;
PARK, BK .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 34 (03) :244-249
[7]  
DARCY PF, 1986, IATROGENIC DIS, P29
[8]   HEPATOTOXICITY OF TETRAHYDROAMINOACRIDINE IN ISOLATED RAT HEPATOCYTES - EFFECT OF GLUTATHIONE AND VITAMIN-E [J].
DOGTEROM, P ;
NAGELKERKE, JF ;
MULDER, GJ .
BIOCHEMICAL PHARMACOLOGY, 1988, 37 (12) :2311-2313
[9]   ENZYMATIC DEFENSES OF THE MOUSE HEART AGAINST REACTIVE OXYGEN METABOLITES - ALTERATIONS PRODUCED BY DOXORUBICIN [J].
DOROSHOW, JH ;
LOCKER, GY ;
MYERS, CE .
JOURNAL OF CLINICAL INVESTIGATION, 1980, 65 (01) :128-135
[10]   A CONTROLLED TRIAL OF TACRINE IN ALZHEIMERS-DISEASE [J].
FARLOW, M ;
GRACON, SI ;
HERSHEY, LA ;
LEWIS, KW ;
SADOWSKY, CH ;
DOLANURENO, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 268 (18) :2523-2529